TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on January 22, 2019. The report addresses a significant regulatory milestone regarding the company's drug candidate, umbralisib.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
On January 22, 2019, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for umbralisib. This designation applies to the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 regimen.
Outlook, Risks, and Management Commentary
The filing incorporates a press release (Exhibit 99.1) detailing the FDA designation. No specific financial guidance, risk factors, or management commentary regarding future financial performance is included in this specific document.
Key Facts for Investor Verification
- Verify the specific clinical data supporting the Breakthrough Therapy Designation for umbralisib in MZL.
- Confirm the timeline for potential regulatory approval following this designation.
- Review the company's most recent 10-K or 10-Q filings for current cash position and burn rate, as this 8-K contains no financial data.